<DOC>
	<DOCNO>NCT01537653</DOCNO>
	<brief_summary>Primary Objective : Assess safety tolerability SAR231893 ( REGN668 ) ascend single subcutaneous ( SC ) dose healthy Japanese adult male subject Secondary Objectives : Assess follow parameter ascend single SC dose healthy Japanese adult male subject - The pharmacokinetics SAR231893 ( REGN668 ) - The immunogenicity SAR231893 ( REGN668 ) - Exploratory analyse pharmacodynamics SAR231893 ( REGN668 )</brief_summary>
	<brief_title>Safety , Tolerability Pharmacokinetics SAR231893 ( REGN668 ) Healthy Japanese Adult Male Subjects</brief_title>
	<detailed_description>Total duration study period per subject 11 week broken follow : Screening period = 2 21 day Treatment period = 57 day , include 1 treatment day</detailed_description>
	<criteria>Inclusion criterion : Japanese adult male subject , 20 45 year age , inclusive . Body weight 50.0 95.0 kg , inclusive , body mass index 18.0 28.0 kg/m2 , inclusive . Certified healthy comprehensive clinical assessment . Having give write informed consent prior undertake studyrelated procedure . Exclusion criterion : Any history presence clinically relevant cardiovascular , pulmonary , gastrointestinal , hepatic , renal , metabolic , hematological , neurological , osteomuscular , articular , psychiatric , systemic , ocular , infectious disease , sign acute illness . Any subject prohibit intensive physical activity throughout study duration . Positive result follow test : hepatitis B surface ( HBs Ag ) antigen , antihepatitis B core antibody ( antiHBc Ab ) , antihepatitis C virus ( antiHCV ) antibody , human immunodeficiency virus ( HIV ) antigen antibody . Positive result urine drug screen ( amphetamines/methamphetamines , barbiturate , benzodiazepine , cannabinoids , cocaine , opiates ) . Serum alcohol level upper limit normal range ( ULN ) . Previous exposure therapeutic investigational biological agent . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>November 2012</verification_date>
</DOC>